Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma
Urological Science, 2019 Immunotherapy with immune checkpoint inhibitors (ICIs) has changed the paradigm of anticancer therapy in many cancer types, including advanced urothelial carcinoma (UC).
Jhe-Cyuan Guo +2 more
doaj +2 more sources
Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
Chinese Medical Journal, 2017 Objective: Sepsis remains a leading cause of death in many Intensive Care Units worldwide. Immunosuppression has been a primary focus of sepsis research as a key pathophysiological mechanism.
Qiang Liu, Chun-Sheng Li
doaj +3 more sources
Indian Journal of Dermatology, 2021 Background: Extramammary Paget's disease (EMPD) is a rare skin cancer and sometimes has fatal prognosis. For progressive cases, therapeutic options are limited.
Hiroyuki Goto +2 more
doaj +3 more sources
Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism [PDF]
Endocrine Connections, 2018 Background: Monoclonal antibodies blocking the programmed cell death-1 (PD-1) or its ligand (PD-L1) are a group of immune checkpoints inhibitors (ICIs) with proven antitumor efficacy.
Jaafar Jaafar +3 more
doaj +5 more sources
Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites [PDF]
Molecules, 2020 Evidence suggests that programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) targeted inhibitors act as an immune checkpoint blockade, indicating that these compounds may be useful in cancer immunotherapy by inhibiting the immune response ...
Nam-Hui Yim +2 more
doaj +3 more sources
Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer [PDF]
Therapeutic Advances in Gastroenterology, 2016 Malignant tumor cells are equipped with mechanisms that can help them escape the surveillance by host immune system. Immune checkpoint molecules can transduce coinhibitory signals to immunocompetent cells and exert immunosuppressive roles in antitumor ...
Xiaojun Liu +3 more
doaj +3 more sources
Status of programmed death-ligand 1 expression in sarcomas [PDF]
Journal of Translational Medicine, 2018 Background Sarcomas are challenging to study because of their rarity and histomorphological complexity. PD1 and PD-L1 inhibitors showed a promising anti-tumor effect in solid tumors, where a relationship between PD-L1 expression and the objective ...
Hyung Kyu Park +5 more
doaj +3 more sources
Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis [PDF]
Critical Care, 2018 Debasree Banerjee +7 more
doaj +3 more sources
Melatonin, programmed death ligand-1, programmed death ligand-1, and cancer: imagine beyond the future? [PDF]
Rev Assoc Med Bras (1992)Soares Junior JM, Sengul I, Sengul D.
europepmc +4 more sources
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer [PDF]
Clinical Cancer Research, 2005 Abstract Purpose: The negative regulatory programmed death-1/programmed death-1 ligand (PD-1/PD-L) pathway in T-cell activation has been suggested to play an important role in tumor evasion from host immunity. In this study, we investigated the expression of PD-L1 and PD-L2 in human esophageal cancer to define their clinical significance
Yuichiro, Ohigashi +14 more
openaire +2 more sources